VC23

Investment approach

Thesis

VC23 invests across all sectors, but our focus is BioTools because they generally scale faster and more efficiently than therapeutics, they typically reach revenue and partnerships earlier than many other biotech sectors, and they often require less capital before exit. We also believe that the Biotool sector will continue to attract steady acquisition interest from global incumbents.Source (opens in a new tab)

Investing status notes

7 Businesses within our active Biotools portfolio